Tirana University of Medicine, Tirana, Albania
DESG Chair, EASD 2018 Highlights Editor
Introduction & therapeutic education
Why should one attend the EASD 2018 Annual Meeting?
What are some of the most relevant areas and interesting studies covered at this meeting?
What are the biggest challenges faced when considering therapeutic education?
Leicester Diabetes Centr - Bloom
Leicester General Hospital, Leicester, UK
ADA-EASD Consensus Report 2018
What is the focus of the ADA/EASD 2018 consensus report on management of hyperglycaemia?
What factors are currently driving treatment decisions in T2D?
What role does diabetes education have in prevention and treatment of T2D?
Willam T. Cefalu
American Diabetes Association, Arlington, VA, USA
The ADA Consensus perspective
What are the implications of the 2018 ADA-EASD consensus report from the perspective of the ADA?
Why has greater emphasis been placed on the use of GLP-1 agonists and SGLT2 inhibitors in the new consensus report?
National Institute for Health and Welfare, Helsinki, Finland
Dasman Diabetes Institute, Dasman, Kuwait
Epidemiology & prevention of T2D
How much actual progress has been made in reversing the global epidemic of T2D?
How has the global epidemiology of T2D changed over the last 5 years and what trends can be expected in the future?
How was the negative trend of T2D and increased cardiometabolic risk reversed in Finland?
Stefano Del Prato
Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy
Can combination therapy be advocated as first-line treatment for T2D?
What factors currently hinder optimal treatment of T2D?
What are the main take-home messages from the HARMONY trial?
As Scientific Chairman of the EFSD, what accomplishments have been achieved and what are the future prospects?
University of Bari Aldo Moro - Division of Endocrinology
University Hospital Policlinico, Bari, Italy
Cardiorenal protection & SGLT2i
Can cardiorenal protection with SGLT2 inhibitors be considered as a goal that has finally been achieved?
Should SGLT2 inhibitors be considered for patient populations that do not have diabetes?
Can renal and CV disease be considered as two faces of the same coin in diabetes?
How can artificial intelligence improve the lives of people with T2D?
Dept. of Medicine, University of Helsinki
Helsinki University Central Hospital, Helsinki, Finland
Diabetes & NAFLD
What tools are commonly used to diagnose NAFLD?
What therapeutic options are now available for patients with T2D and NAFLD?
What are the mainstays of prevention and treatment for NAFLD in patients with T2D?
University College London, London, UK
What exactly is meant by the term ‘urban diabetes’? Is the urban population more susceptible to development of T2D?
What are some of the vulnerabilities for the patient with urban diabetes?
Dept. of Molecular and Clinical Medicine
University of Göteborg, Sweden
Gut microbiota & diabetes
Is there a pathogenic association between gut microbiota and diabetes?
How can differences in gut microbiota translate to differences in glucose metabolism between individuals?
Does gut microbiota represent a novel therapeutic target for diabetes?
Does gut microbiota potentially play a role in the prevention of T2D?
Dept. of Diabetes, Monash University, Melbourne, Victoria, Australia
Famine & future diabetes
Is there evidence for a relationship between T2D and major famine?
What policies might be advocated following a major famine?
What would your recommendations be to the United Nations, international aid organisations and the International Diabetes Federation?